Major South Korean biosimilar manufacturer Celltrion Inc. plans to build a plant in China in a move to directly advance into the world’s second-largest biopharmaceutical market, its chief said.
“We are in the final stage of signing a contract with the Chinese government. We will soon announce details of the plant,” Chairman Seo Jung-jin said during the annual J.P. Morgan Healthcare Conference in San Francisco.
The company’s business roadmap centers on building a plant with a production capacity of 120,000 liters in China to boost capacity amid rising demand.
The planned factory will be the largest production facility in China, according to Celltrion.
The company said it will also launch a system to sell drugs like Remsima SC directly.